News | August 26, 2025
Giant antibody in humans acts like a brace against bacterial toxins
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
Upgrades 2025 full-year CDMO sales and margin outlook
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
The first project will focus on developing an AI-based platform for the sterically guided design of bispecific antibodies
Subscribe To Our Newsletter & Stay Updated
